Literature DB >> 31036341

Absence of Collaterals is Associated with Larger Infarct Volume and Worse Outcome in Patients with Large Vessel Occlusion and Mild Symptoms.

Eric R Kimmel1, Sami Al Kasab1, Jillian B Harvey2, Girish Bathla3, Santiago Ortega-Gutierrez1, Gabor Toth4, Emily M Jaksich1, Ali Sheharyar5, Jorge Roa1, David M Hasan6, Edgar A Samaniego7.   

Abstract

BACKGROUND: Mechanical thrombectomy is the standard of care for patients with large vessel occlusion (LVO) presenting with severe symptoms; however, little is known about the best treatment for patients with LVO and mild symptoms. The absence of good collaterals has been associated with a worse outcome in patients with LVO. In this study, we aim to assess the use of collateral score to identify patients with LVO and mild symptoms that might benefit from mechanical thrombectomy (MT).
METHODS: A retrospective review of prospectively collected data on patients presenting with mild ischemic stroke (National Institute of Health Stroke Scale [NIHSS] <6) and anterior circulation LVO between September 2015 and July 2017 was performed. Collected data included baseline demographics, NIHSS on admission, Alberta Stroke Program Early CT Score (ASPECTS), location of occlusion, collateral score using Tan scoring system, final infarct volume, and 90-day modified Rankin Scale (mRS). Patients who underwent MT were excluded from this analysis. Two multivariable models were used to assess outcomes. A gamma distributed generalized linear regression model with a log link was used to examine the impact on final infarct volume. To predict the odds of a positive 90-day outcome we estimated a logistic regression.
RESULTS: Forty-one patients were identified. Mean age was 67.7-years with 56.1% males. Median NIHSS on admission was 3. The most common vessels involved were the middle cerebral artery (26), internal carotid artery (14), and anterior cerebral artery (1). Twelve patients received intravenous alteplase. Median ASPECTS score was 9, median collateral score was 2.3. Median infarct volume was 10.7 mL. A good functional outcome (mRS 0-2) at 90 days was achieved in 86.4% of patients. There was a negative relationship between collateral score and final infarct volume (-.3134, P = .046). Multivariable regression results showed that with a one-point increase in NIHSS on admission there was a 25% increase in final infarct volume. Higher infarct volume was associated with lower odds of achieving good functional outcome (mRS 0-2) (odds ratio .96, P = .049 [95% confidence interval .918-.999).
CONCLUSIONS: Most patients with anterior circulation LVO and low NIHSS achieve good long-term functional outcome, however, approximately 15% had significant disability. The absence of collaterals correlates with a larger final infarct volume and a worse long-term functional outcome. Collateral score might be a useful tool in identifying patients with LVO and low NIHSS who might benefit from MT.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute stroke imaging; LVO; acute stroke management; cerebral blood flow; cerebral ischemia; collaterals; computed tomography angiography; infarct volume; large vessel occlusion; low NIHSS; mild stroke

Mesh:

Substances:

Year:  2019        PMID: 31036341     DOI: 10.1016/j.jstrokecerebrovasdis.2019.03.032

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  8 in total

1.  Biomechanics and hemodynamics of stent-retrievers.

Authors:  Anna Luisa Kühn; Zeynep Vardar; Afif Kraitem; Robert M King; Vania Anagnostakou; Ajit S Puri; Matthew J Gounis
Journal:  J Cereb Blood Flow Metab       Date:  2020-05-19       Impact factor: 6.200

2.  Collateral status contributes to differences between observed and predicted 24-h infarct volumes in DEFUSE 3.

Authors:  Vaishnavi L Rao; Michael Mlynash; Søren Christensen; Amarnath Yennu; Stephanie Kemp; Greg Zaharchuk; Jeremy J Heit; Michael P Marks; Maarten G Lansberg; Gregory W Albers
Journal:  J Cereb Blood Flow Metab       Date:  2020-05-19       Impact factor: 6.200

3.  Association between Early Ischemic Changes and Collaterals in Acute Stroke: A Retrospective Study.

Authors:  M Laflamme; S Carrondo-Cottin; M-M Valdès; D Simonyan; M-È Audet; J-L Gariépy; M-C Camden; C Gariépy; S Verreault; P Lavoie
Journal:  AJNR Am J Neuroradiol       Date:  2022-09-22       Impact factor: 4.966

4.  Effect of Reconstructive Procedures of the Extracranial Segment of the Carotid Arteries on Damage to the Blood-Brain Barrier.

Authors:  Piotr Terlecki; Stanisław Przywara; Karol Terlecki; Dariusz Janczak; Maciej Antkiewicz; Tomasz Zubilewicz
Journal:  Int J Environ Res Public Health       Date:  2022-05-20       Impact factor: 4.614

5.  In vivo imaging of hemodynamic redistribution and arteriogenesis across microvascular network.

Authors:  Naidi Sun; Bo Ning; Anthony C Bruce; Rui Cao; Scott A Seaman; Tianxiong Wang; Regina Fritsche-Danielson; Leif G Carlsson; Shayn M Peirce; Song Hu
Journal:  Microcirculation       Date:  2019-12-02       Impact factor: 2.628

6.  Induced neuroprotection by remote ischemic perconditioning as a new paradigm in ischemic stroke at the acute phase, a systematic review.

Authors:  Francisco Purroy; Cristina García; Gerard Mauri; Cristina Pereira; Coral Torres; Daniel Vazquez-Justes; Mikel Vicente-Pascual; Ana Vena; Gloria Arque
Journal:  BMC Neurol       Date:  2020-07-02       Impact factor: 2.474

7.  Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies.

Authors:  Elena Meseguer; Devy Diallo; Julien Labreuche; Hugo Charles; Sandrine Delbosc; Gabrielle Mangin; Linsay Monteiro Tavares; Giuseppina Caligiuri; Antonino Nicoletti; Pierre Amarenco
Journal:  J Clin Med       Date:  2020-12-13       Impact factor: 4.241

8.  Determining Clinically-Viable Biomarkers for Ischaemic Stroke Through a Mechanistic and Machine Learning Approach.

Authors:  Ivan Benemerito; Ana Paula Narata; Andrew Narracott; Alberto Marzo
Journal:  Ann Biomed Eng       Date:  2022-04-01       Impact factor: 4.219

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.